Nuala Moran

The US healthcare investor Paul Capital Healthcare is putting $100 million into a new European company set up to fund and manage clinical trials.

The world’s computers may be throwing out heat when active, consuming electricity on stand-by, and polluting the environment when dumped, but now the industry is on a mission.

The reshuffling of EU portfolios brings ‘innovation’ to the policy fore – but we are waiting for details (if they exist) of how it will all work, write Richard L. Hudson and Nuala Moran.

There are signs the financing drought brought on by the credit crunch may be over for European biotechs as investors loosen the purse strings.

Two of the UK’s quoted university technology commercialisation companies are cosying up, with IP Group plc investing £2.9 million in Fusion IP plc.

The 7th annual roll call of the world’s best universities still ranks Europe’s jewels low, with the US taking more than 50 of the top 100 spots.

Governments often find scientific advice unpalatable. But they shouldn’t shoot the messenger, writes Senior Editor Nuala Moran.

A new campaign seeks to persuade regulators to set new rules for approving personalised treatments that are currently in clinical development.

One of Europe’s pre-eminent figures in university technology transfer is standing down as Vice President of Research at ETH Zurich after data were shown to have been falsified.

As his presidency is renewed, José Manuel Barroso says he wants to appoint a chief scientist with a brief to oversee matters scientific across the Commission.